Sunshine Biopharma closes $6.0M public offering with up to $12M additional warrant proceeds

Sunshine Biopharma Inc.

Gross proceeds $6.0M from 12,000,000 units at $0.50/unit; closed May 19, 2026.
Each unit includes one share (or pre-funded warrant) plus two Series C warrants exercisable at $0.50 for five years.
Potential additional $12.0M if Series C warrants fully exercised; no assurance given.
Net proceeds for general corporate purposes and working capital.
Aegis Capital Corp acted as placement agent with 7% fee plus 2% expense allowance.

item 1.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.